CIGALL KADOCH

Insider Reports History

Location
Cambridge, MA
Signature
/s /Allan Reine, M.D., Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by CIGALL KADOCH:

Company Role Class Num Shares Value Price $ Report Date Ownership
Foghorn Therapeutics Inc. Director Common Stock 3,329,379 $27,467,377 $8.25 31 Aug 2022 Indirect
Foghorn Therapeutics Inc. Director Common Stock 295,000 $2,433,750 $8.25 31 Aug 2022 Direct
Foghorn Therapeutics Inc. Director Stock Options (Right to buy) 12,530 $38,342 $3.06 31 Aug 2022 Direct

Insider Reports Filed by CIGALL KADOCH

Symbol Company Period Transactions Value $ Form Type Role Filing Time
FHTX Foghorn Therapeutics Inc. 31 Aug 2022 0 $0 4 Director 02 Sep 2022, 08:07
FHTX Foghorn Therapeutics Inc. 21 Jun 2022 1 $0 4 Director, 10%+ Owner 22 Jun 2022, 20:59
FHTX Foghorn Therapeutics Inc. 14 Dec 2021 1 $0 4 Director, 10%+ Owner 16 Dec 2021, 18:20
FHTX Foghorn Therapeutics Inc. 13 Jul 2021 1 $0 4 Director, 10%+ Owner 14 Jul 2021, 16:53